Profile data is unavailable for this security.
About the company
WuXi Biologics (Cayman) Inc is an investment holding company principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry. The Company mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The Company mainly conducts its business in the domestic and overseas markets.
- Revenue in HKD (TTM)18.31bn
- Net income in HKD3.65bn
- Incorporated2014
- Employees12.74k
- LocationWuXi Biologics (Cayman) IncNo. 108, Meiliang Road, MashanWUXI ChinaCHN
- Websitehttps://www.wuxibiologics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Keymed Biosciences Inc | 380.51m | -386.16m | 9.47bn | 897.00 | -- | 2.95 | -- | 24.89 | -1.48 | -1.48 | 1.44 | 11.47 | 0.0906 | 0.7314 | 26.14 | 424,203.30 | -9.16 | -- | -10.05 | -- | 89.59 | -- | -101.04 | -- | 9.18 | -- | 0.123 | -- | 253.87 | -- | -16.63 | -- | -- | -- |
InnoCare Pharma Ltd | 793.63m | -678.35m | 9.96bn | 1.09k | -- | 1.13 | -- | 12.55 | -0.4022 | -0.4022 | 0.4703 | 4.36 | 0.073 | 1.39 | 3.39 | 728,770.90 | -6.38 | -13.41 | -8.08 | -15.36 | 82.61 | 85.99 | -87.42 | -172.16 | 4.13 | -- | 0.1582 | -- | 18.09 | 240.36 | 28.80 | -- | 66.20 | -- |
RemeGen Co Ltd | 1.16bn | -1.62bn | 19.27bn | 3.62k | -- | 3.15 | -- | 16.66 | -3.01 | -3.01 | 2.15 | 6.87 | 0.1864 | 0.4005 | 4.31 | 319,891.80 | -26.17 | -18.66 | -31.75 | -23.75 | 76.48 | 81.94 | -140.43 | -102.88 | 1.31 | -64.32 | 0.2682 | -- | 40.16 | 148.65 | -51.30 | -- | 59.07 | -- |
Genscript Biotech Corp | 6.56bn | -745.57m | 19.53bn | 6.94k | -- | 1.79 | -- | 2.98 | -0.3539 | -0.3539 | 3.11 | 5.12 | 0.283 | 7.59 | 5.45 | 945,048.00 | -11.97 | -18.34 | -18.27 | -26.15 | 48.78 | 54.68 | -42.30 | -64.91 | 4.65 | -- | 0.1694 | -- | 34.17 | 29.44 | 57.91 | -- | 17.14 | -- |
Akeso Inc | 4.86bn | 2.18bn | 33.68bn | 2.78k | 14.95 | 6.49 | 15.03 | 6.92 | 2.60 | 2.60 | 5.81 | 6.00 | 0.6168 | 0.3749 | 15.98 | 1,750,867.00 | 26.47 | -11.59 | 31.40 | -13.87 | 96.96 | -- | 42.91 | -42.49 | 4.39 | 19.18 | 0.3983 | -- | 440.35 | 337.43 | 273.60 | -- | 63.99 | -- |
Sichuan Kelun-Biotech Biophrmctcl Co Ltd | 1.66bn | -616.96m | 36.41bn | 1.42k | -- | 14.31 | -- | 22.00 | -2.78 | -2.78 | 7.55 | 11.42 | -- | -- | -- | 1,169,903.00 | -- | -- | -- | -- | 49.28 | -- | -37.27 | -- | 2.47 | -34.90 | 0.0251 | -- | 91.62 | -- | 6.81 | -- | -- | -- |
WuXi Biologics (Cayman) Inc | 18.31bn | 3.65bn | 46.76bn | 12.74k | 13.40 | 1.10 | 8.78 | 2.55 | 0.84 | 0.84 | 4.21 | 10.22 | 0.321 | 5.04 | 3.02 | 1,436,813.00 | 6.73 | 8.28 | 8.47 | 10.25 | 40.08 | 43.25 | 20.96 | 27.46 | 2.54 | -- | 0.0939 | 0.00 | 11.56 | 46.38 | -23.09 | 40.07 | 20.32 | -- |
Beigene Ltd | 21.57bn | -6.13bn | 126.42bn | 10.00k | -- | 4.59 | -- | 5.86 | -4.55 | -4.55 | 15.81 | 19.30 | 0.4753 | 1.87 | 7.42 | -- | -13.50 | -26.72 | -18.48 | -33.85 | 74.76 | 83.19 | -28.39 | -120.76 | 1.84 | -- | 0.2339 | -- | 73.65 | 65.47 | 56.00 | -- | 33.46 | -- |
Data as of Jul 05 2024. Currency figures normalised to WuXi Biologics (Cayman) Inc's reporting currency: Hong Kong Dollar HKD
Holder | Shares | % Held |
---|---|---|
Capital Research & Management Co. (World Investors)as of 31 Oct 2022 | 202.45m | 4.75% |
The Vanguard Group, Inc.as of 06 Jun 2024 | 140.00m | 3.28% |
E Fund Management Co., Ltd.as of 31 Dec 2023 | 130.16m | 3.05% |
Schroder Investment Management Ltd.as of 31 May 2024 | 77.15m | 1.81% |
Norges Bank Investment Managementas of 31 Dec 2023 | 70.08m | 1.64% |
BlackRock Fund Advisorsas of 28 Jun 2024 | 69.48m | 1.63% |
Schroder Investment Management (Hong Kong) Ltd.as of 31 Mar 2024 | 69.47m | 1.63% |
BlackRock Advisors (UK) Ltd.as of 28 Jun 2024 | 64.70m | 1.52% |
Hang Seng Investment Management Ltd.as of 07 Jun 2024 | 42.73m | 1.00% |
GF Fund Management Co., Ltd.as of 31 Dec 2023 | 32.65m | 0.77% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.